chiniofon has been researched along with indacaterol* in 2 studies
1 review(s) available for chiniofon and indacaterol
Article | Year |
---|---|
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
There has been a real interest recently in developing once-daily beta(2)-adrenoceptor agonists (ultra-long-acting beta(2)-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic obstructive pulmonary disease (COPD) in an attempt to simplify their management, although an increasing amount of convincing data show an association of LABAs with a rise in asthma-related deaths and life-threatening experiences. This paper reviews the effects of different ultra-LABAs that are at varying stages of development. Arformoterol, carmoterol, indacaterol and GSK-159797 are ultra-LABAs that are likely to be introduced into the market before 2010. It is plausible that once-daily dose administration of an LABA will lead to increased convenience for patients, which may also lead to enhancement of adherence, and may have advantages leading to improved overall clinical outcomes in patients with asthma and COPD. Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Amphetamines; Animals; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Hydroxyquinolines; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2007 |
1 other study(ies) available for chiniofon and indacaterol
Article | Year |
---|---|
[Novel controllers of airway obstruction in COPD patients].
For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency. The once-daily dose administration is an important step which may allow to enhance of patients compliance. Novel long-acting bronchodilators--beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as indacaterol and carmoterol--are under clinical application for the treatment of COPD patients. Moreover, some new long-acting antimuscarinic agents (LAMA) (aclidinium, glycopyrrolate) and dual-action ultra LABA+LAMA combination products are under development. The main target of therapeutic research is to produce a dimmer molecule known as M3 antagonist-beta2 agonist (MABA) bronchodilators which will open the door for a new range of combination products. Topics: Airway Obstruction; Amphetamines; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Humans; Hydroxyquinolines; Indans; Muscarinic Antagonists; Patient Compliance; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |